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giocyte glycocalyx was desialylated to test its protective 
function. Using lectin assays, we demonstrated that the 
main N-glycans in human and mouse cholangiocytes were 
sialylated biantennary structures, accompanied by high ex-
pression of the H-antigen (α 1–2 fucose). Apical neuramini-
dase treatment induced desialylation without affecting cell 
viability, but lowered cholangiocellular resistance to bile ac-
id-induced toxicity: both glycochenodeoxycholate and che-
nodeoxycholate (pK a  ≥ 4), but not taurochenodeoxycholate 
(pK a <2), displayed cholangiotoxic effects after desialylation. 
A 24-hour reconstitution period allowed cholangiocytes to 
recover to a pretreatment bile salt susceptibility pattern. 
 Conclusion: Experimental evidence indicates that an apical 
chol angiocyte glycocalyx with glycosylated mucins and oth-
er glycan-bearing membrane glycoproteins stabilizes the 
‘biliary HCO 3– umbrella’, thus aiding in the protection of hu-
man cholangiocytes against bile acid toxicity. 
 © 2015 S. Karger AG, Basel 
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 Abstract 
 Background: Destruction of cholangiocytes is the hallmark 
of chronic cholangiopathies such as primary biliary cirrhosis. 
Under physiologic conditions, cholangiocytes display a strik-
ing resistance to the high, millimolar concentrations of toxic 
bile salts present in bile. We recently showed that a ‘biliary 
HCO 3– umbrella’, i.e. apical cholangiocellular HCO 3– secretion, 
prevents cholangiotoxicity of bile acids, and speculated on 
a role for extracellular membrane-bound glycans in the sta-
bilization of this protective layer. This paper summarizes 
published and thus far unpublished evidence supporting 
the role of the glycocalyx in stabilizing the ‘biliary HCO 3– um-
brella’ and thus preventing cholangiotoxicity of bile acids. 
 Key Messages: The apical glycocalyx of a human cholangio-
cyte cell line and mouse liver sections were visualized by 
electron microscopy. FACS analysis was used to characterize 
the surface glycan profile of cultured human cholangiocytes. 
Using enzymatic digestion with neuraminidase the cholan-
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 Toxic Bile Salts 
 Destruction of biliary epithelial cells, cholangiocytes, 
is the hallmark of chronic cholangiopathies such as pri-
mary biliary cirrhosis  [1] , with subsequent loss of bile 
ducts and chronic cholestasis  [2, 3] . Under chronic cho-
lestatic conditions, hydrophobic, i.e. potentially toxic, 
bile salts accumulate in the body  [4] and are thought to 
drive disease progression  [2] . Reflecting upon cholangio-
cellular physiology, it is striking that cholangiocytes are 
continuously exposed, without major damage, to the 
most toxic of all body fluids: bile. Hydrophobic bile salts, 
which are present in bile at high, millimolar concentra-
tions, induce apoptosis in other cell types such as hepato-
cytes already at low, micromolar concentrations via spe-
cific signaling pathways  [5, 6] and may even elicit necro-
sis in several cell types  [7] . In striking contrast, human 
cholangiocytes are exposed to millimolar concentrations 
of hydrophobic bile salts under physiologic conditions 
 [1] without significant cytotoxicity.
 Several protective mechanisms help cholangiocytes 
endure their constant exposure to bile. Secretion of phos-
pholipids by hepatocytes allows for the formation of 
mixed micelles, decreasing the concentration of free bile 
salt monomers. Failure to form such mixed micelles, for 
example due to impaired phospholipid secretion in the 
setting of ABCB4 deficiency, leads to ductular damage 
and cholestasis. However, formation of mixed micelles 
insufficiently reduces the concentration of free hydro-
phobic bile salt monomers to low millimolar levels in bile, 
as discussed earlier  [8] .
 The ‘Biliary HCO 3 
– Umbrella’ 
 We have recently hypothesized that excessive biliary 
HCO 3– secretion in humans is a key protective mechanism 
to prevent bile salt-induced cholangiocellular damage 
 [8] . Intracellular accumulation of hydrophobic bile salts 
is a prerequisite for their cytotoxic effects. Passive, carri-
er-independent cell invasion of bile salts is determined by 
their polarity and degree of protonation  [9] . Conjugates 
of chenodeoxycholate (CDC), the predominant toxic bile 
salts in human bile during cholestasis, are among the 
most hydrophobic bile salts in humans. The glycine con-
jugate (GCDC) with a pKa of  ∼ 4 is partially protonated, 
apolar, and thus cell permeable at micromolar amounts 
at a physiologic pH of 7.4. Even minor changes in local 
biliary pH affect the glycine-conjugated bile salt:bile acid 
ratio and, thereby, the sensitivity of cholangiocytes to-
ward glycine-conjugated bile acid-induced damage. Ex-
perimental evidence recently published by our group 
supports our hypothesis of a protective ‘biliary HCO 3–  
umbrella’  [10] : we found that GCDC uptake and GCDC-
induced cholangiocellular apoptosis is pH-dependent in 
vitro  and contained by expression of the main biliary 
HCO 3– exporter, anion exchanger 2. These insights opened 
up new avenues for the development of therapeutic strat-
egies for patients in whom loss of biliary barrier function 
causes cholestatic disease  [11] .
 Having gathered evidence supporting the existence of 
a ‘biliary HCO 3– umbrella’ we hypothesized that physical/
cellular structures are needed to help stabilize the pericel-
lular alkaline milieu. ‘Trapping’ of the HCO 3– -rich peri-
cellular fluid would help the cholangiocyte to maintain an 
alkaline pH close to its apical membrane without the need 
to alkalize the bulk of mainstream bile. In the stomach, a 
mucous layer scaffolds a pH-gradient ranging from pH 
1–2 within the lumen to  ∼ 6–7 just near the cell mem-
brane  [12] . We thus reasoned that a similar principle 
could apply for cholangiocytes. We hypothesized that a 
distinct glycocalyx layer on the apical surface of cholan-
giocytes could be the physical structure stabilizing the 
pericellular pH in the biliary tree.
 The Biliary Glycocalyx 
 A glycocalyx is defined as an extracellular, juxtamem-
branous layer of glycoproteins, glycans, glycosphingolip-
ids and polysaccharides. Some components of the glyco-
 Fig. 1. Visualization of the biliary glycocalyx in a mouse ( a ), hu-
man ( b ) and biliary epithelial cell line ( c ) using transmission elec-
tron microscopy. In the cultured cells in  c , ruthenium red was de-
ployed to selectively stain the glycocalyx ( c adapted from Ho-
henester et al.  [10] ). Fixation of mouse liver tissue was performed 
in McDowell fixative (4% paraformaldehyde, 1% glutaraldehyde, 
0.1  M cacodylate and 4.4 m M CaCl2; pH 7.4), and counterstaining 
was performed with 1% OsO 4 . The immortalized nonmalignant 
human intrahepatic cholangiocyte cell line H69  [26] was cultured 
in a DMEM/F12- (3: 1) based medium as described earlier  [10] . 
Fixation of cultured cells was performed in McDowell fixative,
either containing 0.2% ruthenium red or not (Sigma-Aldrich,
St. Louis, Mo., USA), and counterstaining was performed with 1% 
OsO 4 either supplemented with 0.05% ruthenium red or not. Fixed 
tissue and cells were embedded in epoxy resin, Epon, cut and ana-
lyzed on a Philips EM420 transmission electron microscope (Phil-
ips, Eindhoven, The Netherlands), equipped with an SIS Megaview 
II camera (SIS, Münster, Germany). 
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calyx are structurally coupled to the lipid bilayer as they 
are bound to transmembrane protein domains or sphin-
golipids. Other constituents, such as secreted glycans and 
hyaluronan, are excreted and loosely associated to the 
layer. The glycocalyx is mostly known for its presence on 
the luminal wall of the endothelium, where it forms a 
thick polysaccharide cushion that serves to reduce shear 
stress between passing blood cells and the vessel wall  [13] . 
A role of the glycocalyx in the physiology and pathophys-
iology of other organs has also been described: in the kid-
ney it contributes to the filtering properties of the glo-
meruli  [14] and in the gut it is a mediator of homeostasis 
of the gut flora  [15, 16] . Variations in the molecular com-
position of the glycocalyx present on enterocytes may af-
fect the gut microbiome as has been implicated by the 
recent reports on fucosyltransferase 2 in Crohn’s disease 
 [17] . A thick glycocalyx also plays a central role as a foun-
dation for the mucous layer that stabilizes the tear film on 
the cornea, and may be deficient in patients with dry eye 
symptoms. Artificial tears containing hyaluronic acid, 
one of the structural components of the normal glycoca-
lyx, may provide relief from these symptoms  [18] .
 Fucosyltransferase 2 modifies the composition of the 
glycocalyx by mediating the inclusion of fucose in sugar 
moieties of glycoproteins and glycolipids. Intriguingly, 
recent genome-wide association studies identified inacti-
vating variants at the fucosyltransferase 2 locus to be as-
sociated with primary sclerosing cholangitis  [19] . These 
results are indirect evidence for a role of the glycocalyx in 
cholangiopathies as discussed earlier  [20] .
 Speculating on a role for a glycocalyx on the luminal 
membrane of cholangiocytes, we recently reported that us-
ing specialized electron microscopy protocols a glycocalyx-
like layer could consistently be visualized on these cells in 
normal mouse biliary tree tissue  [8] . This prompted us to 
further investigate the properties of this biliary glycocalyx.
 Tools to Investigate the Glycocalyx 
 Supplemental to electron microscopy and specific stain-
ing methods, quantitative and qualitative staining with lec-
tins allows for the biochemical characterization of the gly-
cocalyx layer. Lectins form a class of proteins that bind to 
specific carbohydrate groups on the cell membranes, and 
can be used to assess the composition of the glycocalyx  [21] . 
Lectins are highly specific, e.g. the lectin  Sambucus nigra 
agglutinin (SNA) binds to α 2–6 -bound sialic acid, while 
 Maackia amurensis agglutinin II (MAA) binds α 2–3 -bound 
sialic acid. Cells stained with lectins can be analyzed, e.g. by 
flow cytometry for quantitative analysis of percentage of 
positive cells and average intensity of lectin binding. As a 
result, a carbohydrate landscape can be identified, provid-
ing insight into the composition of the glycocalyx.
 In addition to specific imaging and biochemical char-
acterization of the biliary glycocalyx, we also experiment-
ed with functional analyses of its protective properties by 
established enzymatic modification of its composition 
 [22] . In our current efforts, we focused on the use of si-
alidases, which cleave off the terminal, negatively charged 
sialic acid residues.
 Key Messages 
 Human and Mouse Cholangiocytes Carry a 
Glycocalyx in vivo and in vitro  
 Tailored fixation and specific staining transmission 
electron microscopy on the biliary epithelium of both 
wild-type BL/6 mice and human samples obtained from 
liver biopsy showed the consistent presence of a 20- to 
40-nm-thick juxtamembranous glycocalyx layer on the 
apical membrane of the biliary epithelium. Representa-
tive stainings of tissues from a BL/6 mouse ( fig. 1 a) and 
from a patient with a history of a primary biliary cirrhosis 
in a stable condition under ursodeoxycholic acid treat-
ment ( fig.  1 b) are shown. We next used an established 
method to enhance glycocalyx visibility by staining with 
ruthenium red and identified the apical glycocalyx on 
cultured human immortalized cholangiocytes ( fig. 1 c).
 Thus, both human and mouse cholangiocytes carry an 
apical glycocalyx, both in vivo  and in vitro.
 Sialic Acids Are Dominantly Present in the Biliary 
Glycocalyx 
 After verification of the presence of an apical glycoca-
lyx on cholangiocytes, we biochemically characterized its 
composition by applying a preestablished lectin panel 
( fig. 2 ). Among O-linked glycans, human cholangiocytes 
predominantly expressed Core 1 (also known as T anti-
gen), which is probably largely not sialylated as it is bound 
by peanut agglutinin. Its precursor Tn antigen was not 
found in significant amounts. The most abundant N-
linked glycan was the mannose diantenna, which is recog-
nized by ConA only in the absence of α-methylmannoside. 
We found the sialic acids on these glycans to be abundant, 
and mostly α 2–6 linked instead of α 2–3 linked (as revealed 
by more prominent binding of SNA than MAA). 
 Furthermore, we identified several more epitopes on 
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 Fig. 2. A lectin panel can be used to investigate the biliary glycoca-
lyx. To assess the respective contributions of different glycans to 
the chemical composition of the biliary glycocalyx, we used a lectin 
panel as described in detail earlier  [21] . In short, cells were brought 
into suspension in serum-containing RPMI medium after short 
trypsinization and were incubated with 5 μg/ml of biotinylated lec-
tins MAA, SNA, and UEA-1 (Vector Laboratories, Burlingame, 
Calif., USA), ConA  (Canavalia ensiformis) ,  Helix pomatia aggluti-
nin (HPA), peanut agglutinin (PNA)  (Arachis hypogaea) , soybean 
agglutinin (SBA)  (Glycin max) and  L. tetragonolobus agglutinin 
 (LTA) (Sigma-Aldrich). Subsequent incubation with Alexa 
488-conjugated streptavidin (Molecular Probes, Carlsbad, Calif., 
USA) allowed for quantitative detection applying the FACSCali-
bur system (BD Biosciences, Franklin Lakes, N.J., USA). For each 
measurement the system was carefully calibrated using Alexa 
488-conjugated streptavidin only to control for potential aspecific 
staining.  a Diagram of flow cytometry-based lectin-binding assay, 
yielding information about the percentage of positive cells and 
about the mean intensity of staining. Data can be plotted on an xy 
axis. Each dot is the average of 5,000 analyzed cells.  b Lectin land-
scape of cultured human immortalized cholangiocytes. The cells 
show a high expression of terminal sialic acid residues, detected by 
SNA (α 2–6 -bound) and MAA (α 2–3 -bound). Each dot shows the 
average staining intensity of 5,000 analyzed cells on the y-axis and 
the percentage of positively staining cells on the x-axis. For all lec-
tins, measurements were repeated in four independent experi-


































   
   
   
   
   
   
   
   
   
   
   



























O-glycans, but given that these O-linked glycans appar-
ently are rather short (as represented by a high intensity 
of peanut agglutinin staining) it is likely that these epi-
topes are mostly linked to N-glycans. We found a high 
expression of α 1–2 fucose, also known as the H-antigen. 
This epitope, recognized by UEA-1, is expressed at sig-
nificant quantities on the endothelium. The Lewis epitope, 
recognized by  Lotus tetragonolobus agglutinin, was barely 
identified. Sialylated LacdiNAc also appears to be present. 
 In conclusion, we established that lectins can be used 
to characterize the composition of the glycocalyx of bili-
ary epithelial cells and showed, amongst other things, the 
presence of substantial amounts of terminal sialic acids 
on its glycocalyx.
 Alteration of Sialylation Status Can Be Reproducibly 
Achieved Enzymatically in vitro  
 Next, we investigated the feasibility to enzymatically 
alter the composition of the biliary glycocalyx. Given 
the observed dominance of sialic acids as terminal sug-
ars on the glycans, neuraminidase was applied, an en-
zyme known to cleave sialic acid groups off apical gly-
cans. Treatment of cultured H69 cells, an immortalized 
human cholangiocyte cell line, with the well-character-
ized enzyme neuraminidase caused a strong desi-
alylation, as documented by flow cytometry ( fig.  3 a), 
without significantly affecting H69 viability. Most likely 
due to ‘opening up’ of the sugar residues normally cov-
ered by terminal sialic acids ( fig.  3 b), we observed a 
strong increase in binding of soybean agglutinin (SBA) 
lectin upon desialylation. Thus, application of neur-
aminidase was efficient in cleaving off sialic acid resi-
dues in the periphery of the glycocalyx without inflict-
ing serious toxicity. 
 Negatively Charged Sialic Acids in the Glycocalyx May 
Stabilize the ‘Biliary HCO 3– Umbrella’ That Protects 
against Apical Protonated Bile Salt Monomers 
 After showing that enzymatic desialylation using 
neuraminidase was feasible in vitro, we compared the 
toxicity of bile salts on cultured H69 cells pretreated with 




























 Fig. 3. Sialic acids are an important con-
stituent of the biliary glycocalyx and can be 
enzymatically removed using neuramini-
dase. To assess the efficacy of desialylation 
by neuraminidase, cells were quickly tryp-
sinated after treatment with neuramini-
dase, as described above, and brought into 
suspension in serum-containing RPMI 
medium. Effects on glycocalyx composi-
tion were assessed by FACS, applying the 
lectin panel as described in figure 2.
 a Treatment with neuraminidase results in 
a strong decrease in exposition of terminal 
sialic acids as represented by a strong re-
duction in SNA (α 2–6 -bound sialic acids) 
and a smaller reduction in MAA (α 2–3 -
bound sialic acids). Desialylation leads to 
an increase of binding of SBA lectin (spe-
cifically binding N-acetylgalactosamine), 
most likely as the residues bound by SBA 
are ‘opened up’ after removal of the sialic 
acid groups. Each bar indicates the mean 
fluorescence intensity of 5,000 analyzed 
cells.  b Diagram of the detection of N-
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the terminal sialic acids would add to the barrier function 
of the glycocalyx. Sialic acid residues in glycans are known 
to stabilize molecules and membranes, and to modulate 
their interactions with the environment. Their compara-
tively strong electronegativity stabilizes the viscosity of 
mucins on the glycocalyx and may regulate the access of 
molecules to the glycans or underlying membrane mol-
ecules such as receptors and transporters. We thus inves-
tigated if desialylation would lead to an enhanced toxic 
effect of luminal bile salts. 
 As shown in  figure 4 a, desialylation increased the sus-
ceptibility to CDC and GCDC, which are mainly unpro-
tonated at the experimental pH. In contrast, desialylation 
did not significantly affect the toxicity caused by TCDC, 
which at a pH of 7.1 is nearly fully present in its unpro-
tonated form due to its low pK a . At an experimental pH 
of 8.0, at which also the majority of CDC molecules is ex-
pected to be present in its unprotonated form, desi-
alylation no longer caused a significant increase in H69 
toxicity. In a control experiment we showed that si-



















a DMSO CDC 500 GCDC 1000 TCDC 1000 M
n = 4–8


















b DMSO CDC 500 GCDC 1000 TCDC 1000 M
n = 4
Control pH 7.1
Neuraminidase 1 U/ml pH 7.1
Control pH 8.0
















c Vehicle 1 mM MBCD 5 mM MBCD 10 mM MBCD
n = 3
 Fig. 4. Desialylation reduces H69 resistance to toxicity induced by 
bile acids as measured by WST-1 viability assays. Confluent native 
H69 cells were cultured in the presence of dimethyl sulfoxide 
(DMSO, control), CDC, GCDC, taurochenodeoxycholate (TCDC) 
or etoposide at indicated concentrations for 4 h at a pH of 8.0, 7.4, 
7.1, 6.7 or 6.4 (20 m M HEPES). To study the role of intact glycoca-
lyx, native confluent H69 cells were washed twice with HBSS and 
incubated with neuraminidase (1 U/ml) in serum-free medium 
(pH 6.7) for 2.5 h. Subsequently, medium was replaced by full cul-
ture medium and cells were either allowed reconstitution for 24 h 
or immediately treated with bile salts (CDC, GCDC, TCDC) or 
DMSO at a pH of 7.1 or 8.0 (20 m M HEPES) and incubated for
18 h. After the induction of cholangiotoxicity, metabolic activity 
was determined as a marker of cell viability by water-soluble tetra-
zolium salt (WST)-1 assays (Roche, Basel, Switzerland) following 
the manufacturer’s instructions. All results are expressed as means 
± SD of at least three independent experiments. Data were ana-
lyzed in GraphPad Prism (GraphPad Software, San Diego, Calif., 
USA). Data were not normally distributed, and a Mann-Whitney 
or Kruskal-Wallis test was applied as indicated and appropriate. A 
level of p < 0.05 was considered statistically significant.  a Desi-
alylation significantly increases susceptibility to toxicity of proton-
ated bile salts ( *  p < 0.05 vs. control, Kruskal-Wallis; adapted from 
Hohenester et al.  [10] ).  b The enhanced toxicity can be nearly ful-
ly reversed by increasing the pH to 8.0 ( *  p < 0.05 vs. control, Krus-
kal-Wallis; adapted from Hohenester et al.  [10] ).  c Sialylation sta-
tus does not affect toxicity by methyl-β-cyclodextrin (MBCD). 
MBCD toxicity is also not modulated by pH. Values are expressed 




















   
   
   
   
   
   
   
   
   
   
   



























alylation status does not affect the toxicity of methyl-β-
cyclodextrin, a known disruptor of biological membranes 
due to its ability to extract cholesterol molecules from the 
lipid bilayer ( fig.  4 c). Desialylation thus increased H69 
susceptibility to bile salt toxicity in a pH-dependent, spe-
cific fashion. This supports the hypothesis that the glyco-
calyx stabilizes a local HCO 3– -rich milieu at the apical 
membrane of the cholangiocyte. 
 The Cholangiocellular Apical Glycocalyx Is Rapidly 
Reconstituted and Regains Its Protective Properties 
following Artificial Desialylation  
 To test the reversibility of the desialylation caused by 
neuraminidase treatment, H69 cells were allowed to re-
constitute their glycocalyx before they were used in bile 
salt toxicity assays. An 18-hour incubation in normal 
growth medium after neuraminidase treatment led to a 
nearly full recovery of the amount of terminal sialic acids 
on H69 cells as measured by FACS ( fig. 5 b). In addition, 
after this reconstitution period, the neuraminidase-treat-
ed cells were no longer more susceptible to bile acid-in-
duced toxicity as compared to cells treated with vehicle 
control ( fig.  5 a). Insults to the glycocalyx composition 
can thus be overcome by the epithelium by reconstitution 
of its original glycan composition. 
 Conclusions 
 In chronic cholangiopathies such as primary biliary 
cirrhosis, the contribution of the pathogenetic factors 
that have been identified so far remains controversial. 
While rarefaction of bile ducts is a histopathologic hall-
mark of the disease, it is under debate whether cholangio-
cellular damage is the cause or consequence of the auto-
immune attack towards bile ducts  [2] . However, there is 
increasing evidence that biliary damage triggers autoim-
munity in this disease  [23, 24] . It therefore seems crucial 
to better understand and characterize cholangiocellular 
pathophysiology in order to further unravel the patho-
genesis of chronic cholangiopathies.




























 Fig. 5. Enhanced bile acid susceptibility by enzymatic desialylation 
can be reversed by reconstitution of the biliary glycocalyx.  a An 
18-hour reconstitution of the glycocalyx after desialylation revers-
es the enhanced toxicity of bile acids upon desialylation.  b Recon-
stitution of the glycocalyx after desialylation by neuraminidase, 
shown on a flow cytometry plot depicting SNA lectin binding. 
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 We have recently proposed that the striking resistance 
of the biliary epithelium against the toxic bile salts that 
physiologically are present in bile at high, millimolar con-
centrations at least partly can be explained by the pres-
ence of a ‘biliary HCO 3– umbrella’  [8] . This ‘biliary HCO 3–
 umbrella’ alkalizes the bile close to the apical membrane, 
fosters the deprotonation of apolar bile acids to charged 
bile salts and thus prevents their uncontrolled cell entry 
and toxicity  [10] . Genetic defects causing malfunctioning 
of this HCO 3– -rich protective layer may predispose indi-
viduals to develop bile salt-induced cholangiocyte toxic-
ity. In case of cell necrosis, apoptosis or senescence, this 
may cause autoantigens to become available to the im-
mune system, thus providing a possible starting point for 
biliary autoimmune disease. 
 Here, we reviewed the current evidence supporting the 
hypothesis that a cholangiocellular glycocalyx, expressed 
on the apical membrane of biliary epithelial cells, is an-
other protective mechanisms and that it might act, in 
part, via physical stabilization of the ‘biliary HCO 3– um-
brella’.
 To the best of our knowledge, we are the first to visu-
ally and biochemically describe the presence and function 
of a glycocalyx layer on the apical membrane of cholan-
giocytes  [8, 10] . By specific staining and electron micros-



















































































 Fig. 6. Proposed model of the biliary glycocalyx supporting the 
biliary bicarbonate umbrella. Electrochemical repulsion by elec-
tronegative charges, shown in red in the figure (color in online 
version only), may both prohibit access of bile salts to the mem-
brane and could ‘trap’ secreted HCO 3– near the plasma membrane. 
No. 1: cholangiocytes prevent the uptake of potentially harmful 
bile salts from the bile duct lumen by secreting large amounts of 
HCO 3– , which shifts the balance in the acid-base reaction of bile 
acids towards their salt form. As shown in No. 2, the biliary glyco-
calyx forms a physical barrier that limits the access of the depro-
tonated bile salts to the plasma membrane, in which the electro-
negative charge of the sialic acids plays a crucial role. Lastly in No. 
3, we speculate that the relative negativity of the outer part of the 
glycocalyx, due to the high amounts of terminal sialic acids, may 
form a repulsive barrier to HCO 3– secreted by the cholangiocyte, 
effectively ‘trapping’ HCO 3– within the glycocalyx which causes a 
higher local pH near the cell membrane. This more alkaline pH will 
lead to rapid deprotonation of bile acids that despite other protec-
tive mechanisms did manage to get close to the plasma membrane, 
thus prohibiting them from easily transferring to the cytosol.
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40 nm on the apical membrane of cholangiocytes. This 
was confirmed on both liver tissues of mouse and man 
and on cultured immortalized human cholangiocytes. 
This layer of  ∼ 20–40 nm should suffice to allow for the 
generation of a local, pericellular microenvironment that 
may differ greatly from the milieu in bulk luminal bile, 
e.g. by retaining secreted compounds. 
 Thus, the pericellular pH may be alkalized by stabiliza-
tion of the ‘biliary HCO 3– umbrella’, i.e. physically pre-
venting secreted HCO 3– to be flushed away by bulk lumi-
nal bile. Although the production of HCO 3– by biliary ep-
ithelial cells may effectively alkalize the pH in the bile duct 
lumen, altering the pericholangiocellular milieu would be 
much more efficient when stabilized by a glycocalyx. In 
addition to such physical protection, the positive charge 
of sugar moieties in the inner part of the glycocalyx might 
help in retaining negatively charged HCO 3– ( fig.  6 ). In 
concert, the cholangiocellular glycocalyx may stabilize a 
juxtacellular alkaline layer in a similar fashion as has been 
described for the stomach epithelium  [12] .
 The glycan composition of the biliary glycocalyx as de-
fined using lectin-binding assays identified abundant si-
alic acid residues among the most terminal components 
of the glycocalyx. The functional interpretation of this 
finding could be that the negative charge of this outer part 
of the glycocalyx may form a repulsive barrier to unpro-
tonated bile salts, which equally carry a negative load, and 
minimize their pericellular concentration.
 This notion is supported by the experiments that 
showed a physiologic function of the cholangiocellular 
glycocalyx in preventing bile salt-induced toxicity. As ex-
pected, at basal conditions human cholangiocytes were 
resistant to cellular damage inflicted by GCDC, which is 
the most abundant hydrophobic, toxic bile salt in human 
bile. After desialylation of the glycocalyx by neuramini-
dase treatment, GCDC (pK a >4) toxicity was exacerbated 
about 4-fold as shown by viability assays. CDC (pK a >4) 
but not TCDC (pK a <2) toxicity was also significantly in-
creased by neuraminidase pretreatment, which supports 
our hypothesis that the glycocalyx specifically adds to the 
barrier function of the ‘biliary HCO 3– umbrella’ against 
protonated bile acids. TCDC has a similar hydrophobic-
ity as GCDC but, with a lower pK a value, it is fully depro-
tonated and thus electrically charged at physiologic pH. 
This prevents its passive cell entry almost independently 
of local pH. These findings are in line with earlier reports 
showing that the transgression of charged particles is 
modulated by the glycocalyx on the endothelial wall  [14, 
25] .
 In summary, we brought together all published and 
thus far unpublished evidence that a glycocalyx is active-
ly maintained on the apical side of cholangiocytes. This 
biliary glycocalyx with glycosylated mucins and other
glycan-bearing membrane proteins may physically and 
chemically stabilize the ‘biliary HCO 3– umbrella’. Bio-
chemical analysis of the composition of the glycocalyx 
identified negatively charged sialic acid residues that 
dominate the outer branches of the glycocalyx tree. This 
may add another protective effect against bile salt-in-
duced cell injury by repelling charged bile salts from the 
pericellular space, minimizing their effective concentra-
tion at the biliary epithelium.
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